BullFrog AI Holdings, Inc. announced that it has identified multiple potential therapeutic targets, including three novel targets, for colorectal cancer using the Company's proprietary AI-driven platform, bfLEAP??. The newly identified targets will be validated through BullFrog AI's ongoing collaboration with the J. Craig Venter Institute (JCVI), a genomics research and innovation institution.JCVI will utilize its expertise in target validation and functional genomic screening to further investigate the potential of these targets in colorectal cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | +2.08% | -1.01% | -9.51% |
1st Jan change | Capi. | |
---|---|---|
-9.51% | 22.69M | |
+48.64% | 54.63B | |
-6.44% | 39.92B | |
+37.07% | 38.82B | |
+14.28% | 26.86B | |
-11.17% | 26.22B | |
-21.40% | 18.78B | |
+25.64% | 12.21B | |
+0.96% | 12.16B | |
+27.04% | 11.94B |
- Stock Market
- Equities
- BFRG Stock
- News Bullfrog AI Holdings, Inc.
- BullFrog AI Announces Identification of Novel Potential Drug Targets for Colorectal Cancer Using Its AI-Driven bfLEAP? Platform